

# **Title: Industry payments to anesthesiologists in the United States between 2014 and 2022**

Anju Murayama<sup>1,2\*</sup>

## **Affiliations:**

<sup>1</sup> School of Medicine, Tohoku University, Sendai City, Miyagi, Japan

<sup>2</sup> Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York City, NY, USA

\*Corresponding author

## **Correspondence**

Anju Murayama

School of Medicine, Tohoku University, 2-1 Seiryomachi, Aoba ward, Sendai City, Miyagi, 980-0872, Japan

Telephone: 81-22-717-8006

Email address: ange21tera@gmail.com

## **Conflicts of interest statement:**

None declared.

## **Word counts, number of figures and tables, and reference counts:**

Word counts: 2958 words for main body and 245 words in abstract

Number of Figures and tables: 3 figures and 1 table.

Number of references: 51 references

## **Funding statement:**

None declared.

## **Author contribution:**

Anju Murayama: conceptualization; methodology; resource; software; formal analysis; investigation; writing - original draft; writing - review & editing; visualization; study administration

## **Ethical approval information:**

37 Institutional board review and approval were not required for this study, as this study is  
38 designed as a non-human subjects study of freely available public data.

39

40 **Key Words:**

41 Open Payments Database; Sunshine Act; United States; ethics; conflict of interest, pain  
42 medicine

43

44 **Abstract:**

45 **Background:**

46 Financial relationships between physicians and the healthcare industry could be  
47 beneficial to improve patient care, but could lead to conflicts of interest. However,  
48 there was no study specifically evaluating the extent of financial relationships between  
49 anesthesiologists and the healthcare industry in the United States.

50  
51 **Methods**

52 Using the Open Payments Database between 2014 and 2022, this longitudinal cross-  
53 sectional study examined the size, prevalence and trends of general (non-research)  
54 payments made by the healthcare industry to all anesthesiologists in the United States.

55  
56 **Results:**

57 Over the nine-year period, 67.0% of all anesthesiologists received general payments  
58 totaling \$272.0 million over nine years, while 21.0% to 35.3% of anesthesiologists  
59 received one or more general payments each year. Median annual general payments to  
60 anesthesiologists ranged from \$57 to \$115. The top 1%, 5%, and 10% of  
61 anesthesiologists received 73.4%, 90.3%, and 94.8% of all general payments,  
62 respectively. There were no constant yearly trends in the total amounts and per-  
63 anesthesiologist general payments between 2014 and 2019, but significant declines  
64 occurred in 2020, likely due to the COVID-19 pandemic. Pain medicine physicians  
65 received the highest median general payments of \$4,426 in nine-year combined total  
66 amounts, followed by addiction medicine (\$431), critical care medicine (\$277), and  
67 general anesthesiology (\$256).

68  
69 **Conclusion:**

70 This study reveals significant financial relationships between the healthcare industry  
71 and anesthesiologists, with a disproportionate concentration of payments among a  
72 minority of anesthesiologists. While no clear trends in payments were evident before  
73 the pandemic, there was a substantial reduction during the COVID-19 outbreak.

74

## 75 **Main body of the manuscript**

### 76 **Introduction**

77 While certain interactions between physicians and the healthcare industry, such as  
78 sharing experiences and collaborating on research, can benefit patients through drug  
79 and device development and improved care, they may also create conflicts of interest  
80 among physicians.[1] To enhance transparency in these relationships, the United States  
81 (US) enacted the Physician Payments Sunshine Act in 2010. This act requires  
82 pharmaceutical and medical device manufacturers to disclose their financial  
83 transactions with physicians on a federal online database, the Open Payments Database,  
84 since 2014.[2] Utilizing this database, numerous previous studies have demonstrated  
85 widespread financial relationships between physicians and the healthcare industry  
86 across various specialties other than anesthesiology.[2-11]

87  
88 Anesthesiologists are responsible for a considerable proportion of opioid prescriptions,  
89 accounting for 8.9% of all opioid-related prescriptions in the US, with primary care  
90 physicians and nurse practitioners prescribing the majority of opioids.[12-14] Prior  
91 research has revealed that non-research payments to physicians from opioid  
92 manufacturers were significantly associated with increased opioid prescriptions at the  
93 individual physician level[13,15-18] and higher opioid overdose deaths at the county  
94 level.[19] However, the extent of financial relationships between anesthesiologists and  
95 the healthcare industry in the US has not been well-documented. This study aims to  
96 assess the size and prevalence of industry payments to anesthesiologists.

### 98 **Methods**

#### 99 ***Study design, participants, and data collection***

100 This longitudinal cross-sectional study examines the extent and trends of non-research  
101 payments to all anesthesiologists in the US using the Open Payments Database.  
102 Following the Physician Payments Sunshine Act, all pharmaceutical and medical  
103 device companies are required to disclose financial transfers exceeding \$100 annually  
104 or \$10 per payment to physicians, nurse practitioners (since 2021), and teaching  
105 hospitals. The reported payments have been disclosed on the Open Payments Database  
106 since August 2013, but full-year payment data have been available since 2014.

107  
108 All anesthesiologists in the US were identified as physicians whose primary specialty  
109 was anesthesiology and subspecialties, and their profile data were extracted from the  
110 Centers for Medicare and Medicaid Services National Plan and Provider Enumeration

111 System database. All general payments to anesthesiologists were extracted from the  
112 Open Payments Database from 2014 to 2022, matching their National Provider  
113 Identifier number, as previously noted.[3,9,20,21]

#### 114 ***Data analyses***

115 Descriptive analysis was conducted on the extracted payment data. For  
116 anesthesiologists who received payments, per-anesthesiologist payments were  
117 calculated. Additionally, yearly trends in the number of anesthesiologists receiving  
118 payments and per-anesthesiologist payments were examined using population-  
119 averaged generalized estimating equations (GEE) with robust adjustment at the  
120 individual physician level. The trend in total amounts of annual payments was  
121 examined with a linear regression model, adjusting for the impact of the COVID-19  
122 pandemic using interrupted time series (ITS) analysis.[4,21-23] The annual number of  
123 anesthesiologists receiving payments and per-anesthesiologist payments were  
124 examined using a modified log-linked GEE model with Poisson distribution and  
125 negative binomial GEE model, respectively.[3,9,20] General payments for royalties,  
126 ownership interests, acquisitions, debt forgiveness, and long term medical supply or  
127 device loan were excluded from the trend analysis, as only small number of  
128 anesthesiologists received substantial amounts (royalties and ownership interest) or the  
129 payment categories were newly introduced since 2021 data (acquisitions, debt  
130 forgiveness, and long-term medical supply or device loan). As subgroup analyses, the  
131 study performed the GEE trend analyses excluding anesthesiologists who were  
132 deactivated and/or newly activated after 2014, to exclude new and retired physicians  
133 from the study sample. Inflation in US dollars was adjusted to 2022-dollar values in all  
134 analyses using the U.S. Bureau of Labor Statistics Consumer Price Index  
135 calculator.[3,23]

136 Additionally, the payments data were analyzed by payment categories, anesthesiologist  
137 subspecialties, and companies making payments. Differences in per-anesthesiologist  
138 payment and likelihood to receive payments by subspecialty were evaluated with a chi-  
139 square test and a Kruskal Wallis test. All data extraction and statistical analysis were  
140 performed using Python 3.9.12 (Python Software Foundation, Beaverton, OR, USA),  
141 Microsoft Excel, version 16.0 (Microsoft Corp., Redmond, WA, USA), and Stata  
142 version 17.0 (StataCorp, College Station, TX, USA).

#### 143 ***Ethical clearance***

144 Given that the publicly available data set per the Sunshine Act reporting guidelines,

Institutional board review and approval were not required for this study, as it was designed as a non-human subjects study of freely available public data.

## Results

Out of 61,305 anesthesiologists registered in the NPPES database, 67.0% (41,041) received at least one general payment from 1373 companies between 2014 and 2022, totaling \$271,950,702 in inflation-adjusted amounts. Median nine-year combined total amounts of general payments per anesthesiologist were \$291 (interquartile range [IQR]: \$108–\$974), while the mean was \$6,626 (standard deviation: \$66,792). The top 1%, 5%, and 10% of anesthesiologists received 73.4%, 90.3%, and 94.8% of all general payments over the nine years, respectively (Figure 1).

### *Payment trends between 2014 and 2022*

Annual trends showed that 21.0% to 35.3% of anesthesiologists received one or more general payments each year between 2014 and 2022. The total amounts of general payments decreased from \$37 million in 2015 to \$33 million in 2019 and further to \$21.7 million in 2020 during the COVID-19 pandemic. Median annual general payments to anesthesiologists ranged from \$57 to \$115 (Table 1).

The GEE model indicated no constant trends in the amounts, counts, and per-anesthesiologist general payments between 2014 and 2019 (Table 1). However, the number of anesthesiologists with general payments increased by 1.8% (95% confidence interval [95% CI]: 1.5–2.0,  $p < 0.001$ ) each year. Total annual amounts of general payments significantly decreased by 72.4% (95% CI: -84.4% to -60.4%,  $p < 0.001$ ) in 2020 compared to those between 2014 and 2019. Similarly, both the number of anesthesiologists receiving general payments and per-anesthesiologist payment amounts significantly decreased by 43.2% (95% CI: -44.2% to -42.1%,  $p < 0.001$ ) and 59.5% (95% CI: -65.2% to -52.9%,  $p < 0.001$ ) in 2020, respectively. However, there were significant recovery trends in all variables between 2020 and 2022.

Subgroup analyses excluding newly activated anesthesiologists showed similar trends in the total annual amounts of payments and per-anesthesiologist payment amounts (Supplemental Material 1). The number of anesthesiologists receiving general payments slightly increased by 0.5% (95% CI: 0.3%–0.8%,  $p < 0.001$ ), indicating that the increasing trend observed in the previous GEE model was primarily due to new

183 anesthesiologists receiving general payments.

184

### 185 ***Payments by category and company***

186 In payment amount, speaking compensation not related to continuing medical  
187 education (CME) program accounted for the largest proportion (29.3%) of all general  
188 payments, followed by consulting payments (20.9%). Food and beverage payments  
189 made up 15.5% of all general payments but were received by 66.2% of  
190 anesthesiologists.

191

192 In payment amounts, speaking compensation not related to continuing medical  
193 education (CME) program is the largest payment categories occupying 29.3% (\$79.7  
194 million) of all general payments, followed by consulting payments (20.9%, \$56.8  
195 million) (Supplemental Material 2). Food and beverage payments accounted for 15.5%  
196 (\$42.2 million) of all general payments, but were received by 66.2% of all  
197 anesthesiologists and the number of food and beverage payments occupied 87.5%  
198 (1,183,671) of general payments. Only 3.2% (1,944) and 4.9% (2,988) of  
199 anesthesiologists received the speaking compensations not related to CME program  
200 and consulting payments, respectively. The highest per-payment values were \$111,162  
201 in acquisition payments, \$31,687 in royalty or license payments, \$24,662 in ownership  
202 payments. Per-payment value were \$2,976 in consulting payments and \$2,772 in  
203 speaking compensations for non-CME program, while it was \$36 in food and beverage  
204 payments.

205

206 Among 1373 companies, the top 10 and 30 companies accounted for 41.9% (\$113.9  
207 million) and 67.8% (\$184.5 million) of all general payments, respectively  
208 (Supplemental Material 3). Pacira Pharmaceuticals made the largest general payments  
209 (\$19.8 million), followed by Medtronic USA (\$15.1 million), Boston Scientific (\$13.7  
210 million), Halyard Health (\$11.2 million), and Abbott Laboratories (\$11.0 million).

211

### 212 ***Payments by subspecialty***

213 The proportion of anesthesiologists receiving general payments over the nine-year  
214 period was highest in pain medicine (89.5%), followed by addiction medicine (69.5%)  
215 and general anesthesiology (65.7%) (Figure 2). Pain medicine physicians received the  
216 highest median general payments of \$4,426 (IQR: \$1,077–\$12,881), followed by  
217 addiction medicine (\$431 [IQR: \$177–\$2,030]), critical care medicine (\$277 [IQR:  
218 \$113–\$1,081]), and general anesthesiology (\$256 [IQR: \$98–\$717]) (Figure 3). There

219 were significant differences by subspecialty in the proportion of anesthesiologists  
220 receiving one or more general payments over the nine-years ( $p < 0.001$  in chi-square  
221 test) and per-anesthesiologist general payments ( $p < 0.001$  in Kruskal Wallis test). While  
222 pain medicine physicians were 6.8% (4,164 out of 61,305) of all anesthesiologists  
223 included in this study, they received 38.1% (\$103.6 million) of all general payments  
224 from the healthcare industry.

225  
226 Regarding payment trends by subspecialty, only pain medicine exceeded the majority  
227 of anesthesiologists receiving general payments each year (Supplemental Material 4).  
228 Median per-anesthesiologist general payments were the highest in pain medicine  
229 (\$326–\$732), followed by addiction medicine (\$71–\$196) and critical care medicine  
230 (\$69–\$139).

## 231 232 **Discussion**

233 This study is the first analysis to assess the magnitude and extent of general payments  
234 provided to all anesthesiologists in the United States. The findings demonstrate that  
235 more than \$271 million in general payments were made to 67.0% of all  
236 anesthesiologists over the nine-year period, with only a minority of anesthesiologists  
237 receiving payments each year. Moreover, a large proportion of the general payments  
238 were received by a small number of anesthesiologists. The study also reveals  
239 differences in general payment patterns within anesthesiology subspecialties, with pain  
240 medicine physicians receiving the highest median general payments, primarily from  
241 pharmaceutical companies marketing opioids. Pain medicine physicians received more  
242 than 17 times higher general payments in median amounts than general  
243 anesthesiologists. Although there were no continuing trends in payments between 2014  
244 and 2019, both the number of anesthesiologists receiving general payments and per-  
245 anesthesiologist general payments significantly decreased in 2020. Compared to the  
246 findings from previous studies, this study would provide important insight into the  
247 transparency of the financial relationship between anesthesiologists and the healthcare  
248 industry.

249  
250 First, this study found that the median annual general payments to anesthesiologists  
251 ranged from \$57 to \$115 each year. Compared to previous studies, this study indicates  
252 that anesthesiologists received fewer general payments from the healthcare industry  
253 than other medical specialists in the US. For instance, Marshall and her colleagues  
254 reported that median general payments per physician were \$186 in family medicine



255 physicians, \$251 in general surgeons, \$453 in colorectal surgeons, and \$860 in thoracic  
 256 surgeons in 2015.[2] Another studies based on the same study design among internal  
 257 medicine subspecialties reported that median annual general payments were \$197 to  
 258 \$220 in infectious disease specialists[6], \$379 to \$440 in pulmonologists[3], \$395–  
 259 \$590 in allergy and clinical immunology[4], \$632 in medical oncology[24], \$730 to  
 260 \$812 in rheumatologists[21], \$725 to \$847 in cardiologists.[22] Additionally, given  
 261 mean annual wage for anesthesiologists was \$302,970 according to 2022 estimates  
 262 from the U.S. Bureau of Labor Statistics,[25] the majority of anesthesiologists have not  
 263 received large general payments compared to their annual salary as an anesthesiologist.

264  
 265 An intriguing observation from this study is the significant variation in general  
 266 payments among anesthesiology subspecialties. Notably, pain medicine physicians  
 267 received substantially higher median general payments compared to other  
 268 anesthesiologists and even certain specialists from different medical fields. Median  
 269 nine-year payment amounts to pain medicine physicians were 17.3 times larger than  
 270 those to general anesthesiologists (\$4,426 vs \$256). Additionally, compared to other  
 271 specialists, median annual general payments to pain medicine physicians (\$326–\$732)  
 272 were as same as or higher than several surgery and internal medicine specialists such  
 273 as general surgeons,[2] pulmonologists,[3] allergists,[4] and medical oncologists.[2,24]  
 274 These large payments to pain medicine physicians were made by pharmaceutical  
 275 companies marketing opioids in the United States, such as INSYS Therapeutics,  
 276 Depomed, Purdue Pharma, and Pfizer. Intense marketing activities by opioid  
 277 manufacturers to physicians and healthcare community have been well documented  
 278 since the early 2000s.[15-19,26] Hadland et al. reported that pain medicine physicians  
 279 received the third largest general payments related to opioid of all specialists between  
 280 2013 and 2015.[18] This finding warrants further investigation and raises questions  
 281 about the potential influence of these financial relationships on pain medicine practice  
 282 and decision-making. Given the well-documented association between opioid-related  
 283 payments and increased opioid prescriptions, healthcare costs,[17,19,26] and opioid  
 284 overdose deaths,[19] it is crucial for pain medicine physicians to be cautious and  
 285 transparent in their financial interactions with opioid manufacturers. While this study  
 286 does not establish any undue influence of industry payments on anesthesiologists, it  
 287 underscores the importance of vigilance and adherence to conflicts of interest  
 288 guidelines to maintain the integrity of clinical, education, and research practices.[1,27-  
 289 29] Further research is warranted to explore the implications of these financial  
 290 interactions on clinical decision-making, healthcare practices, and patient outcomes.

291  
 292 Furthermore, only the top 1% and 10% of anesthesiologists received nearly three  
 293 fourths and 95% of all general payments, respectively. This finding is consistent with  
 294 many previous studies in this research field.[3,5,8-11,21-23,30-34] Feng et al. reported  
 295 that the top 10% of dermatologists received more than 90% of all general payments  
 296 from the healthcare industry in 2014.[8] The top 10% of pulmonologists received  
 297 83.7% of all general payments between 2013 and 2021.[3] As shown in previous  
 298 studies, the healthcare industry made the large amounts of general payments to the  
 299 small fraction of physicians who are in leading positions such as clinical guideline  
 300 authors,[7,32,35-37] journal editors,[32,37-40] society board members,[32,41] and  
 301 principal investigators of industry-sponsored clinical trials.[28,42] These influential  
 302 physicians are called key opinion leaders.[42,43] Although some studies positively  
 303 stated the role of key opinion leaders who are supported by the healthcare industry  
 304 when they advocate as an independent expert for better, cheaper and safer products on  
 305 behalf of patients and healthcare communities,[33] most of previous cases have not  
 306 shown such positive effects. Instead, financial conflicts of interest between healthcare  
 307 industry and key opinion leaders have questioned the influence of experts on  
 308 recommendations and practices.[27,44-47] Current global standards for managing  
 309 conflicts of interest require these influential physicians such as clinical guideline  
 310 authors and journal editors to minimize their financial interactions with the healthcare  
 311 industry and at least to be transparent in their relationships with the healthcare industry.  
 312 Nevertheless, Wyssa et al. found that there was no disclosure of authors' conflicts of  
 313 interest in 36% of clinical guidelines published in ten high-impact anesthesiology  
 314 academic journals between 2008 and 2018.[48] Additionally, some studies in other  
 315 specialties found that there were large amounts of undeclared and under-declared  
 316 financial relationships between the healthcare industry and influential physicians.[49]  
 317 Further transparency in financial relationships between the healthcare industry and the  
 318 influential physicians is needed. Future studies should evaluate the extent and accuracy  
 319 of disclosed financial relationships between the healthcare industry and influential  
 320 anesthesiologists.

321  
 322 Another notable aspect of this study is its evaluation of trends in general payments  
 323 over time. Despite the implementation of the Open Payments Database to increase  
 324 transparency in physicians-industry relationships, some experts predicted that  
 325 increased transparency and increased public pressure and scrutiny would lead to a  
 326 decrease in physicians-industry financial relationships for non-research purposes.[50]

327 This study found limited changes in the general payments patterns between 2014 and  
 328 2019. This observation would raise questions about the effectiveness of the Open  
 329 Payments Database in altering anesthesiologists-industry financial relationships.  
 330 However, the COVID-19 pandemic had a profound impact on general payments in  
 331 2020, with a substantial decrease in both the amounts and the number of  
 332 anesthesiologists receiving payments. This finding is consistent with previous studies  
 333 in other specialties and overall.[6,21,22,30,31,51] Inoue et al. found that the amounts  
 334 of general payments decreased by more than 44% overall in 2020 compared to those in  
 335 2019.[51] Santamaria et al. reported that general payments to surgeons decreased by  
 336 about 50% in 2020.[30] This decline in general payments to anesthesiologists can be  
 337 attributed to the pandemic-related restrictions and measures that disrupted traditional  
 338 marketing strategies and in-person interactions. Interestingly, the industry seemed to  
 339 adapt quickly to the changing landscape, as evidenced by the significant recovery  
 340 trends in payments between 2020 and 2022, while the total amount of general  
 341 payments to anesthesiologists in 2022 was still about 70% of those before the  
 342 pandemic (\$23.8 million in 2022 vs \$33.0 million in 2019). This adaptation likely  
 343 involved a shift towards utilizing online platforms and virtual engagement to maintain  
 344 communication and marketing efforts during the pandemic.[21,22,30] Considering the  
 345 current significant downsizing of pharmaceutical representatives, the use of online  
 346 platforms and virtual marketing will continue even after the pandemic.

347  
 348 The limitations of this study include the possibility of errors in public databases, such  
 349 as the NPPES and Open Payments Database, as pointed out in previous studies.[3,21]  
 350 Second, there would be unmeasured confounding factors that may impact trends in  
 351 general payments to anesthesiologists.[3,9] Third, there would be differences in the  
 352 number of anesthesiologists between the U.S. Centers for Medicare & Medicaid  
 353 Services NPPES database and other databases such as the American Board of  
 354 Anesthesiology and the Association of American Medical Colleges databases, as these  
 355 are structured based on different methods and physicians self-declared their primary  
 356 specialty in the NPPES database even though they did not have board-certification as  
 357 an anesthesiologist.[2,20] Fourth, the amounts of general payments to anesthesiologists  
 358 would be influenced by non-measured anesthesiologists' demographic factors such as  
 359 physician age, workplace type, position, and graduated school. However, these  
 360 variables are not available from the NPPES and the Open Payments Database. Finally,  
 361 there would be unmeasured interactions such as free drug samples not covered by the  
 362 Open Payments Database and the Physician Payments Sunshine Act.

363

364 In summary, this study reveals that over \$271 million in general payments were made  
365 to 67.0% of anesthesiologists between 2014 and 2022, with only a minority receiving  
366 these payments annually. The majority of payments were received by the small group  
367 of anesthesiologists. While there were no significant trends in payments from 2014 to  
368 2019, the COVID-19 pandemic caused a notable decline in 2020. However, payments  
369 showed a remarkable recovery between 2020 and 2022. These findings emphasize the  
370 importance of transparency in financial relationships and the need to address potential  
371 conflicts of interest. Continued efforts to promote transparency are essential for  
372 maintaining trust in healthcare practices.

373

### 374 **Acknowledgments**

375 I would like to thank Ms. Megumi Aizawa for her dedicated support of my research. I  
376 declared no financial conflicts of interest and did not receive any financial support for  
377 this study from any entity. For proofreading parts of the presented text, I used the  
378 freely available pre-trained ChatGPT (version 3.5) model developed by OpenAI in  
379 order to check and proofread the manuscript for language, spelling and grammatical  
380 errors. I checked and edited the text for unintended plagiarism, and verified all facts  
381 and values that I used from the ChatGPT outputs before the manuscript submission.

382

### 383 **References**

- 384 1. Institute of Medicine. *Conflict of Interest in Medical Research, Education, and*  
385 *Practice*. Washington, DC: The National Academies Press, 2009.
- 386 2. Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD, Hattangadi-  
387 Gluth JA. Types and Distribution of Payments From Industry to Physicians in  
388 2015. *Jama* 2017; **317**: 1774-84.
- 389 3. Murayama A, Kugo H, Saito Y, Saito H, Tanimoto T, Ozaki A. A Nine-year  
390 Investigation of Healthcare Industry Payments to Pulmonologists in the United  
391 States. *Ann Am Thorac Soc* 2023.
- 392 4. Murayama A, Kamamoto S, Saito H, Tanimoto T, Ozaki A. Industry payments  
393 to allergists and clinical immunologists in the United States during the  
394 coronavirus disease 2019 pandemic. *Ann Allergy Asthma Immunol* 2022; **129**:  
395 635-6.
- 396 5. Annapureddy A, Murugiah K, Mingos KE, Chui PW, Desai N, Curtis JP.  
397 Industry Payments to Cardiologists. *Circ Cardiovasc Qual Outcomes* 2018; **11**:  
398 e005016.

- 399 6. Murayama A, Nakano K, Kamamoto S, et al. Trend in industry payments to  
400 infectious disease physicians in the United States: a seven-year analysis of  
401 nonresearch payments from the Open Payments Database between 2014 and  
402 2020. *Clin Microbiol Infect* 2022; **28**: 1655 e1- e4.
- 403 7. Nusrat S, Syed T, Nusrat S, Chen S, Chen WJ, Bielefeldt K. Assessment of  
404 Pharmaceutical Company and Device Manufacturer Payments to  
405 Gastroenterologists and Their Participation in Clinical Practice Guideline  
406 Panels. *JAMA Netw Open* 2018; **1**: e186343.
- 407 8. Feng H, Wu P, Leger M. Exploring the Industry-Dermatologist Financial  
408 Relationship: Insight From the Open Payment Data. *JAMA Dermatol* 2016;  
409 **152**: 1307-13.
- 410 9. Murayama A, Hirota S. Industry payments to pathologists in the USA between  
411 2013 and 2021. *J Clin Pathol* 2023.
- 412 10. Muffly TM, Giamberardino WL, Guido J, Weterings R, Bastow B, Sheeder J.  
413 Industry Payments to Obstetricians and Gynecologists Under the Sunshine Act.  
414 *Obstet Gynecol* 2018; **132**: 9-17.
- 415 11. Parikh K, Fleischman W, Agrawal S. Industry Relationships With Pediatricians:  
416 Findings From the Open Payments Sunshine Act. *Pediatrics* 2016; **137**:  
417 e20154440.
- 418 12. Guy GP, Jr., Zhang K. Opioid Prescribing by Specialty and Volume in the U.S.  
419 *Am J Prev Med* 2018; **55**: e153-e5.
- 420 13. Inoue K, Figueroa JF, Orav EJ, Tsugawa Y. Association between industry  
421 payments for opioid products and physicians' prescription of opioids:  
422 observational study with propensity-score matching. *J Epidemiol Community*  
423 *Health* 2020; **74**: 647-54.
- 424 14. Agarwal A, Roberts A, Dusetzina SB, Royce TJ. Changes in Opioid Prescribing  
425 Patterns Among Generalists and Oncologists for Medicare Part D Beneficiaries  
426 From 2013 to 2017. *JAMA Oncology* 2020.
- 427 15. Hollander MA, Donohue JM, Stein BD, Krans EE, Jarlenski MP. Association  
428 between opioid prescribing in Medicare and pharmaceutical company gifts by  
429 physician specialty. *Journal of general internal medicine* 2020; **35**: 2451-8.
- 430 16. Hadland SE, Cerdá M, Li Y, Krieger MS, Marshall BDL. Association of  
431 Pharmaceutical Industry Marketing of Opioid Products to Physicians With  
432 Subsequent Opioid Prescribing. *JAMA Internal Medicine* 2018; **178**: 861-3.
- 433 17. Zezza MA, Bachhuber MA. Payments from drug companies to physicians are  
434 associated with higher volume and more expensive opioid analgesic prescribing.

- 435 *PLoS One* 2018; **13**: e0209383.
- 436 18. Hadland SE, Krieger MS, Marshall BDL. Industry Payments to Physicians for  
437 Opioid Products, 2013–2015. *American Journal of Public Health* 2017; **107**:  
438 1493-5.
- 439 19. Hadland SE, Rivera-Aguirre A, Marshall BDL, Cerdá M. Association of  
440 Pharmaceutical Industry Marketing of Opioid Products With Mortality From  
441 Opioid-Related Overdoses. *JAMA Network Open* 2019; **2**: e186007-e.
- 442 20. Marshall DC, Tarras ES, Rosenzweig K, Korenstein D, Chimonas S. Trends in  
443 Industry Payments to Physicians in the United States From 2014 to 2018. *Jama*  
444 2020; **324**: 1785-8.
- 445 21. Murayama A, Kamamoto S, Higuchi K, Shigeta H, Ozaki A. Trend in Industry  
446 Payments to Rheumatologists in the United States During the COVID-19  
447 Pandemic Between 2013 and 2021. *J Rheumatol* 2023; **50**: 575-7.
- 448 22. Murayama A, Kamamoto S, Shigeta H, Ozaki A. Industry Payments During the  
449 COVID-19 Pandemic to Cardiologists in the United States. *CJC Open* 2023; **5**:  
450 253-5.
- 451 23. Murayama A. Industry-sponsored research funding to infectious disease  
452 physicians in the United States between 2013 and 2021. *Clin Microbiol Infect*  
453 2023.
- 454 24. Marshall DC, Moy B, Jackson ME, Mackey TK, Hattangadi-Gluth JA.  
455 Distribution and Patterns of Industry-Related Payments to Oncologists in 2014.  
456 *JNCI: Journal of the National Cancer Institute* 2016; **108**.
- 457 25. U.S. Bureau of Labor Statistics. Occupational Employment and Wage Statistics,  
458 2022. <https://www.bls.gov/oes/current/oes291211.htm> (accessed July 20/2023).
- 459 26. Fleischman W, Agrawal S, Gross CP, Ross JS. Association of Pharmaceutical  
460 Manufacturer Payments to Physicians and Prescribing Dosage of Opioids. *J*  
461 *Gen Intern Med* 2019; **34**: 1074-6.
- 462 27. Nejstgaard CH, Bero L, Hrobjartsson A, et al. Association between conflicts of  
463 interest and favourable recommendations in clinical guidelines, advisory  
464 committee reports, opinion pieces, and narrative reviews: systematic review.  
465 *BMJ* 2020; **371**: m4234.
- 466 28. Ahn R, Woodbridge A, Abraham A, et al. Financial ties of principal  
467 investigators and randomized controlled trial outcomes: cross sectional study.  
468 *BMJ* 2017; **356**: i6770.
- 469 29. Dubois MY. American Academy of Pain Medicine Ethics Council Statement on  
470 Conflicts of Interest: Interaction between Physicians and Industry in Pain



- 471 Medicine. *Pain Medicine* 2010; **11**: 257-62.
- 472 30. Santamaria-Barria JA, Nelson H, Jiang H, et al. Open Payments Data Analysis  
473 of General and Fellowship-trained Surgeons Receiving Industry General  
474 Payments from 2016 to 2020: Payment Disparities and COVID-19 Pandemic  
475 Impact. *Ann Surg* 2023.
- 476 31. Khunte M, Zhong A, Khunte A, et al. Industry Payments to Radiologists During  
477 the Last 5 Years and Impact of COVID-19 Pandemic. *J Am Coll Radiol* 2023;  
478 **20**: 597-604.
- 479 32. Wright K, Meyers DE, Chisamore TM, et al. Industry Relationships With  
480 Medical Oncologists: Who Are the High-Payment Physicians? *JCO Oncology*  
481 *Practice* 2022; **18**: e1164-e9.
- 482 33. Storino A, Vigna C, Polanco-Santana JC, et al. Disparities in industry funding  
483 among Colorectal Surgeons: a cross-sectional study. *Surgical Endoscopy* 2022;  
484 **36**: 6592-600.
- 485 34. Murayama A, Kamamoto S, Saito H, Tanimoto T, Ozaki A. Trends in Industry  
486 Payments to Diabetologists and Endocrinologists in the United States During  
487 the COVID-19 Pandemic. *Cureus* 2022; **14**: e32643.
- 488 35. Tabatabavakili S, Khan R, Scaffidi MA, Gimpaya N, Lightfoot D, Grover SC.  
489 Financial Conflicts of Interest in Clinical Practice Guidelines: A Systematic  
490 Review. *Mayo Clin Proc Innov Qual Outcomes* 2021; **5**: 466-75.
- 491 36. Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T. Letter to the editor:  
492 Are clinical practice guidelines for hepatitis C by the American Association for  
493 the Study of Liver Diseases and Infectious Diseases Society of America  
494 evidence based? Financial conflicts of interest and assessment of quality of  
495 evidence and strength of recommendations. *Hepatology* 2022; **75**: 1052-4.
- 496 37. Kamamoto S, Murayama A, Kusumi E, et al. Evaluation of financial  
497 relationships between Japanese certified pediatric hematologist/oncologists and  
498 pharmaceutical companies: a cross-sectional analysis of personal payments  
499 from pharmaceutical companies between 2016 and 2019. *Pediatr Blood Cancer*  
500 2022; **69**: e29891.
- 501 38. Liu JJ, Bell CM, Matelski JJ, Detsky AS, Cram P. Payments by US  
502 pharmaceutical and medical device manufacturers to US medical journal  
503 editors: retrospective observational study. *BMJ* 2017; **359**: j4619.
- 504 39. Nguyen D-D, Murad L, Nguyen AX-L, et al. Industry Payments to American  
505 Editorial Board Members of Major Urology Journals. *European Urology* 2023.
- 506 40. Murayama A, Mamada H, Shigeta H, et al. Financial Relationships Between

- 507            Pharmaceutical Companies and Rheumatologists in Japan Between 2016 and  
508            2019. *JCR: Journal of Clinical Rheumatology* 2023;  
509            10.1097/RHU.0000000000001922.
- 510    41.    Murayama A, Kamamoto S, Kawashima M, et al. Cross-sectional analysis of  
511            pharmaceutical payments to Japanese board-certified gastroenterologists  
512            between 2016 and 2019. *BMJ Open* 2023; **13**: e068237.
- 513    42.    Scher JU, Schett G. Key opinion leaders - a critical perspective. *Nat Rev*  
514            *Rheumatol* 2021; **17**: 119-24.
- 515    43.    Moynihan R. Key opinion leaders: independent experts or drug representatives  
516            in disguise? *BMJ* 2008; **336**: 1402-3.
- 517    44.    Johnson L, Stricker RB. Attorney General forces Infectious Diseases Society of  
518            America to redo Lyme guidelines due to flawed development process. *J Med*  
519            *Ethics* 2009; **35**: 283-8.
- 520    45.    Murayama A, Kida F, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial and  
521            Intellectual Conflicts of Interest Among Japanese Clinical Practice Guidelines  
522            Authors for Allergic Rhinitis. *Otolaryngol Head Neck Surg* 2022; **166**: 869-76.
- 523    46.    Steinbrook R. Guidance for guidelines. *N Engl J Med* 2007; **356**: 331-3.
- 524    47.    McCoy MS, Pagán O, Donohoe G, Kanter GP, Litman RS. Conflicts of Interest  
525            of Public Speakers at Meetings of the Anesthetic and Analgesic Drug Products  
526            Advisory Committee. *JAMA Intern Med* 2018; **178**: 996-7.
- 527    48.    Wyssa D, Tramèr MR, Elia N. Reporting of conflicts of interest and of  
528            sponsorship of guidelines in anaesthesiology. A cross-sectional study. *PLoS*  
529            *One* 2019; **14**: e0212327.
- 530    49.    Taheri C, Kirubarajan A, Li X, Lam ACL, Taheri S, Olivieri NF. Discrepancies  
531            in self-reported financial conflicts of interest disclosures by physicians: a  
532            systematic review. *BMJ Open* 2021; **11**: e045306.
- 533    50.    Pham-Kanter G. Act II of the Sunshine Act. *PLoS Med* 2014; **11**: e1001754.
- 534    51.    Inoue K, Figueroa JF, Kondo N, Tsugawa Y. Changes in industry marketing  
535            payments to physicians during the covid-19 pandemic: quasi experimental,  
536            difference-in-difference study. *BMJ Medicine* 2022; **1**: e000219.

537  
538  
539



Table 1. General payments to anesthesiologists between 2014 and 2022

Variables	Payment year									Relative annual average percentage change (95% confidence interval), % <sup>b</sup>		
	2014	2015	2016	2017	2018	2019	2020	2021	2022	2014-2019	2014-2019 vs 2020-2022	2020-2022
Total payment amounts, \$	30,201,179	36,998,756	35,662,138	33,336,258	33,964,108	32,988,544	21,705,999	23,302,673	23,791,047	0.8 (-2.6 to 4.3)	-72.4 (-84.4 to -60.4)*	9.9 (5.1 – 14.7)*
Number of physicians with payments, n (%)	17,061 (27.8)	18,177 (29.7)	21,642 (35.3)	19,466 (31.8)	19,215 (31.3)	19,245 (31.4)	12,887 (21.0)	16,277 (26.6)	17,709 (28.9)	1.8 (1.5 – 2.0)*	-43.2 (-44.2 to -42.1)*	14.7 (13.8 – 15.6)*
Payments per physician, \$ <sup>c</sup>												
Median (IQR)	112 (33–280)	115 (35–306)	115 (34–282)	104 (32–270)	99 (30–255)	109 (30–255)	57 (22–197)	74 (25–213)	68 (24–211)	0.7 (-2.4 to 3.9) <sup>c</sup>	-59.5 (-65.2 to -52.9)* <sup>c</sup>	17.2 (9.7 – 25.1)* <sup>c</sup>
Average (SD)	1,770 (16,773)	2,035 (26,148)	1,648 (13,435)	1,713 (14,203)	1,768 (15,892)	1,714 (19,874)	1,684 (32,580)	1,432 (14,750)	1,343 (17,421)			

Legend: <sup>a</sup> Per-physician payment was calculated among physicians receiving payments. <sup>b</sup> General payments for royalties, ownership interests, acquisitions, debt forgiveness, and long-term medical supply or device loan were excluded from the trend analysis, as only small number of anesthesiologists received substantial amounts (royalties and ownership interest) or the payment categories were newly introduced since 2021 data (acquisitions, debt forgiveness, and long-term medical supply or device loan). <sup>c</sup> These values were estimated relative annual average percentage change among all anesthesiologists registered in the NPPES database including those who did not receive any payments.

\*p<0.001. Abbreviations: 95% confidence interval (95% CI), interquartile range (IQR), SD (standard deviation)




Figure 1. Concentration of general payments to anesthesiologists between 2014 and 2022.




Figure 2. Proportions of anesthesiologists receiving at least one general payment between 2014 and 2022 by subspecialty.




Figure 3. Median general payments per anesthesiologist among anesthesiologists who received general payments between 2014 and 2022 by subspecialty.

